Clinical Trials Logo

Clinical Trial Summary

The purpose of this clinical trial is to determine if Domperidone in a dose of 40 mg daily can prevent worsening of walking ability in people secondary progressive MS. The number of participants in this study will be 62. A maximum of 75 people with secondary progressive MS will be included. Each patient will be followed for 12 months from inclusion. Domperidone is a medication which has been shown to increase levels of the hormone prolactin. The best understood function of prolactin is the stimulation of milk production in women after delivery. However, the increase in prolactin levels seen in patients treated with standard doses of Domperidone (in doses of up to 80mg per day) usually does not lead to clinical symptoms. Prolactin has been shown to improve myelin repair in mice. Domperidone therefore may also improve myelin repair in people with MS. Domperidone is currently approved in Canada to treat slow moving bowels and nausea, for instance in patients with Parkinson's Disease or Diabetes Mellitus, where too slowly moving bowels can cause constipation. Domperidone is available as a tablet that is usually taken four times per day. Doses up to 80mg per day may be used but we estimate that a dose of only 40mg daily will be needed to stimulate myelin repair. Domperidone is usually well tolerated.


Clinical Trial Description

Primary objective

To demonstrate non-futility of domperidone for reducing progression of disability, as measured with the timed 25 foot walk (T25FW), in secondary progressive Multiple Sclerosis (SPMS).

Secondary objectives

- To assess the safety of domperidone in the study population for the duration of the study.

- To assess the effect of domperidone on hand dexterity as measured with the 9HPT

- To assess the effect of domperidone on cognition, as measured with the SDMT

- To assess the effect of domperidone on health related quality of life, as measured with the MSQOL-54

- To assess the effect of domperidone on fatigue, as measured with the MFIS

- To establish the Simon-2-stage model as a study model in MS research. The application of this methodology to studies in progressive MS will have important consequences for the design and conduct of clinical and translational research in progressive MS, in particular for phase II trials in progressive MS ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02308137
Study type Interventional
Source University of Calgary
Contact
Status Completed
Phase Phase 2
Start date February 2015
Completion date January 3, 2020

See also
  Status Clinical Trial Phase
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT02273635 - Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS Phase 1/Phase 2
Recruiting NCT05961644 - Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS). Phase 2/Phase 3
Completed NCT06436131 - The Effects of In-phase Bilateral Exercise in People With Progressive Multiple Sclerosis N/A
Recruiting NCT05013463 - Hydroxychloroquine and Indapamide in SPMS Phase 2
Recruiting NCT04918225 - Motor Asymmetry in Progressive Multiple Sclerosis Patients
Completed NCT01982942 - Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis Phase 2
Recruiting NCT05204459 - MS-ResearchBiomarkerS
Terminated NCT02430532 - BG00012 and Disability Progression in Secondary Progressive Multiple Sclerosis (SPMS) Phase 3
Completed NCT00888277 - Bayer/Cognitive Assessments With Multiple Sclerosis Subjects N/A
Completed NCT05663853 - An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
Recruiting NCT05168384 - Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis Phase 1/Phase 2
Completed NCT02305264 - Imaging of Intracerebral Inflammation in MS N/A
Terminated NCT00468611 - Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis Phase 3
Recruiting NCT05496881 - Exercise Effects in Multiple Sclerosis N/A
Completed NCT05357833 - Novel Imaging Markers in SPMS Early Phase 1
Not yet recruiting NCT06390930 - Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS N/A
Completed NCT02506751 - Open-label Study of Liothyronine in MS Phase 1
Completed NCT00587691 - Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis Phase 1/Phase 2
Recruiting NCT04260711 - Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS). N/A